ALEXANDRIA, Va. (November 17, 2026) — The Centers for Medicare & Medicaid Services (CMS) recently released the final rule for its Global Benchmark for Efficient Drug Pricing (GLOBE) model. Several new studies find the model will lead to very limited savings for beneficiaries. Saul Anuzis, president of the 60 Plus Association, issued the following statement in response to the finalized rule:
“The 60 Plus Association strongly opposes the GLOBE rule. Seniors deserve reforms that lower their prescription drug costs while protecting their access to the medicines they need. Importing foreign price controls into Medicare is not the answer.
“The GLOBE model would effectively determine what manufacturers owe Medicare for certain Part B medicines based on prices dictated by foreign governments. Those artificially low prices often come at patients’ expense: health systems in these countries frequently offer fewer new medicines, and patients often wait longer to receive new treatments. Using these prices as Medicare benchmarks risks replicating the same restrictions in the United States.
“These models would not produce meaningful savings for seniors, either. Under GLOBE, the widespread use of supplemental coverage means many Part B beneficiaries could see little direct reduction in their out-of-pocket costs. Seniors could ultimately face more barriers to their medicines without receiving the financial relief they were promised.
“Critically, this model would undermine future drug development. Adopting foreign price controls would reduce expected returns on innovation and make investments in new medicines even riskier — ultimately leading to fewer breakthroughs for cancer, Alzheimer’s disease, and other serious conditions that disproportionately affect older Americans.
“America’s seniors should not have to accept fewer treatment options today and fewer medical advances tomorrow. CMS should instead pursue patient-centered reforms that lower costs without sacrificing access or innovation.”
###